



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/08B), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/815,388
Filing Date	March 31, 2004
First Named Inventor	Pablo Caviades
Group Art Unit	1651
Examiner Name	Allison M. Ford
Attorney Docket Number	USF-167XC1

Sheet 1 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
aj	R1	ALLEN, D.D. <i>et al.</i> "Impaired cholinergic function in cell lines derived from the cerebral cortex of normal and trisomy 16 mice" <i>Eur. J. Neurosci.</i> , 2000, 12:3259-3264.	
aj	R2	ALLEN, D.D. <i>et al.</i> "A dorsal root ganglia cell line derived from trisomy 16 fetal mice, a model for Down syndrome" <i>NeuroReport</i> , 2002, 13:491-496.	
aj	R3	ANDREWS, B.A. <i>et al.</i> "Factors for the Optimization of the Culture of Neuronal Cell Lines for the Development of Cell Transplant Material" poster presented at the Cell Culture & Engineering Conference in Snowmass, CO, April 1-6, 2002.	
aj	R4	ARRIAGADA, C. <i>et al.</i> "Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission?" <i>Amino Acids</i> , 2000, 18:363-373.	
aj	R5	BARROS, V.G. <i>et al.</i> "Corticosterone down-regulates dopamine D ₄ receptor in a mouse cerebral cortex neuronal cell line" <i>Neurotoxicity Res.</i> , 2003, 5(5):369-374.	
aj	R6	BHADRIARAJU, K. and HANSEN, L.K. "Hepatocyte adhesion, growth and differentiated function on RGD-containing proteins" <i>Biomaterials</i> , 2000, 21:267-272.	
aj	R7	CÁRDENAS, A. <i>et al.</i> "Cell lines derived from hippocampal neurons of the normal and trisomy 16 mouse fetus (a model for down syndrome) exhibit neuronal markers, cholinergic function, and functional neurotransmitter receptors" <i>Experimental Neurology</i> , 2002, 177:159-170.	
aj	R8	CÁRDENAS, A. <i>et al.</i> "Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome" <i>J. Neurosci. Res.</i> , 2002, 68:46-58.	
aj	R9	CÁRDENAS, A.M. <i>et al.</i> "Calcium signals in cell lines derived from the cerebral cortex of normal and trisomy 16 mice" <i>NeuroReport</i> , 1999, 10:363-369.	
aj	R10	CARMONA, M.T. and CAVIEDES, R. "Effects of factors derived from a tumor clonal cell line on DNA synthesis of transformed and non transformed cells" <i>Cell Biol Int Rep.</i> , 1985, 9(3):209-218.	
aj	R11	CAVIEDES, P. <i>et al.</i> "Calcium fluxes, ion currents and dihydropyridine receptors in a new immortal cell line from rat heart muscle" <i>J. Mol. Cell Cardiol.</i> , 1993, 25:829-845.	
aj	R12	CAVIEDES, R. and STANBURY, J.B. "Studies on a cell line from a functional rat thyroid tumor in continuous culture" <i>Endocrinology</i> , 1976, 99:549-554.	
aj	R13	CAVIEDES, R. <i>et al.</i> "Tetrodotoxin-sensitive sodium channels in a continuously cultured cell line derived from the adult rat cerebellum" <i>Brain Res.</i> , 1986, 365(2):259-268.	

Examiner
Signature

Allison M. Ford

Date

Considered

14 Sept. 2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/815,388		
		Filing Date	March 31, 2004		
		First Named Inventor	Pablo Caviades		
		Group Art Unit	1651		
		Examiner Name	Allison M. Ford		
Sheet	2	of	4	Attorney Docket Number	USF-167XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ag	R14	CAVIEDES, R. <i>et al.</i> "Identification of kallikrein in cultures of adult renal cells" <i>Cell Biol Int Rep</i> , 1987, 11(10):735-743.	
ag	R15	CAVIEDES, R. <i>et al.</i> "Ion channels in a skeletal muscle cell line from a Duchenne muscular dystrophy patient" <i>Muscle Nerve</i> , 1994, 17(9):1021-1028.	
ag	R16	CHEN, G. <i>et al.</i> "Photoimmobilization of sulfated hyaluronic acid for antithrombogenicity" <i>Bioconj. Chem.</i> , 1997, 8:730-734.	
ag	R17	CHIU, D.T. <i>et al.</i> "Patterned deposition of cells and proteins onto surfaces by using three-dimensional microfluidic systems" <i>Proc. Acad. Sci. USA</i> , 2000, 97:2408-2413.	
ag	R18	CLÉMENCE, J.F. <i>et al.</i> "Photoimmobilization of a bioactive laminin fragment and pattern-guided selective neuronal cell attachment" <i>Bioconj. Chem.</i> , 1995, 6:411-417.	
ag	R19	DELAMARCHE, E. <i>et al.</i> "Patterned diversity of immunoglobulins to surfaces using microfluidic networks" <i>Science</i> , 1997, 276:779-781.	
ag	R20	EAGLE, H. <i>et al.</i> "Myo-inositol as an essential growth factor for normal and malignant human cells in tissue culture" <i>J. Biol. Chem.</i> , 1956, 123:845-847.	
ag	R21	EAGLE, H. "Media for Animal Cell Culture" <i>Tissue Culture Association Manual</i> , 1976, 3:517-519.	
ag	R22	EAGLE, H. "Amino acid metabolism in mammalian cell cultures" <i>Science</i> , 1959, 130:432-437.	
ag	R23	EAGLE, H. "Nutrition needs of mammalian cells in tissue culture" <i>Science</i> , 1955, 122:501-504.	
ag	R24	FOLCH, A. and TONER, M. "Cellular micropatterns on biocompatible materials" <i>Biotechnol. Prog.</i> , 1998, 14:338-392.	
ag	R25	HORACEK, M.J. <i>et al.</i> "Adult adenohypophyseal cells express β_1 integrins and prefer laminin during cell-substratum adhesion" <i>In Vitro Cell. Dev. Biol.</i> , 1994, 30A:35-40.	
ag	R26	LERNHARDT, W. and SPEAR, D. "Improved adherent mammalian cell transfection with ProNectin™ F recombinant attachment factor" <i>Strategies in Molecular Biology</i> , 1993, 5:48-50.	

Examiner Signature	<i>Allison M. Ford</i>	Date Considered	14 Sept. 2005
--------------------	------------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/815,388		
		Filing Date	March 31, 2004		
		First Named Inventor	Pablo Caviedes		
		Group Art Unit	1651		
		Examiner Name	Allison M. Ford		
Sheet	3	of	4	Attorney Docket Number	USF-167XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ag	R27	LIBERONA, J.L. <i>et al.</i> "Expression of ion channels during differentiation of a human skeletal muscle cell line" <i>J. Muscle Res. Cell Motility</i> , 1997, 18:587-598.	
ag	R28	LIBERONA, J.L. <i>et al.</i> "Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines" <i>Muscle & Nerve</i> , 1998, 21:902-909.	
ag	R29	LIU, V.A. <i>et al.</i> "Engineering protein and cell adhesivity using PEO-terminated triblock polymers" <i>J. Biomed. Mater. Res.</i> , 2002, 60:126-134.	
ag	R30	LOM, B. <i>et al.</i> "A versatile technique for patterning biomolecules onto glass coverslips" <i>J. Neurosci. Methods</i> , 1993, 50:385-397.	
ag	R31	LWEBUGA-MUKASA, J.S. "A Mn ²⁺ -enhanced, RGD-dependent adhesion technique for isolation of adult rat type II alveolar epithelial cells for immediate functional studies" <i>Am. J. Respir. Cell Mol. Biol.</i> , 1994, 10:347-354.	
ag	R32	MAUNG, K. <i>et al.</i> "Requirement for focal adhesion kinase in tumor cell adhesion" <i>Oncogene</i> , 1999, 18:6824-6828.	
ag	R33	NEEDEL, D.L. <i>et al.</i> "Long-term support by injured brain extract of a subpopulation of ciliary ganglion neurons purified by differential adhesion" <i>Neurochem. Res.</i> , 1987, 12(10):901-907.	
ag	R34	PARIS, I. <i>et al.</i> "Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line" <i>J. Neurochem.</i> , 2001, 77:519-529.	
ag	R35	RUOSLAHTI E. and PIERSCHBACHER, M.D. "New perspectives in cell adhesion: RGD and Integrins" <i>Science</i> , 1987, 238:491-497.	
ag	R36	SALAZAR, J. <i>et al.</i> "Intrastriatal implantation of RCSN adult rat substantia nigra-derived cells reverts rotational behaviour in 6OH dopamine lesioned rats" Abstract No. 300.8, Society for Neuroscience, Washington, D.C., 2003	
ag	R37	SINGHVI, R. <i>et al.</i> "Engineering cell shape and function" <i>Science</i> , 1994, 264:696-698.	
ag	R38	STEDRONSKY, E.R. <i>et al.</i> "Injection molding of ProNectin® dispersed in polystyrene for the fabrication of plastic ware activated towards attachment of mammalian cells" <i>Materials Research Society Symposium Proceedings</i> , 1994, 330:157-164.	
ag	R39	VARANI, J. <i>et al.</i> "Use of recombinant and synthetic peptides as attachment factors for cells on microcarriers" <i>Cytotechnology</i> , 1993, 13:89-98.	

Examiner Signature	<i>Allison M. Ford</i>	Date Considered	14 Sept 2005
--------------------	------------------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/815,388
		Filing Date	March 31, 2004
		First Named Inventor	Pablo Caviedes
		Group Art Unit	1651
		Examiner Name	Allison M. Ford
		Attorney Docket Number	USF-167XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ad	R40	ZHENG, J. <i>et al.</i> "Measurements of growth cone adhesion to culture surfaces by micromanipulation" <i>J. Cell Biol.</i> , 1994, 127(6, Part 2):2049-2060.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature	<i>Allison M. Ford</i>	Date Considered	14 Sept. 2005
--------------------	------------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.